Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder

Urology

Volumn 56, Issue 2, 2000, Pages 228-231

  Mian, Christine ^a   Lodde, Michele ^b   Haitel, Andrea ^b   Egarter Vigl, Eduard ^a   Marberger, Michael ^b   Pycha, Armin ^c  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

^b UNIVERSITY OF VIENNA   (Austria)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; CYTOKERATIN 18; CYTOKERATIN 8; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADENOMA; ADULT; AGED; ARTICLE; BIOPSY; BLADDER CARCINOMA; CANCER STAGING; CLINICAL TRIAL; CYSTITIS; CYSTOSCOPY; DIAGNOSTIC ACCURACY; FOLLOW UP; HEMATURIA; HISTOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; INTERMETHOD COMPARISON; INVERTED PAPILLOMA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; TRANSURETHRAL RESECTION; URINALYSIS; URINE CYTOLOGY; UROGENITAL TRACT TUMOR; UROLITHIASIS; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; CHROMATOGRAPHY; COMPLEMENT FACTOR H; CYSTOSCOPY; EVALUATION STUDIES; FOLLOW-UP STUDIES; HUMANS; KERATINS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0033915695     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00664-6     Document Type: Article

References (21)

1. Wiener H.G., Mian C., Haitel A., et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol. 159:1998;1876-1880.
2. Chopin D.K., Laurent J.C. Monoclonal antibodies in bladder cancer cytology. World J Urol. 9:1991;75-78.
3. Fradet Y., Cordon-Cardo C. Critical appraisal of tumor markers in bladder cancer. Semin Urol. 11:1993;145-153.
4. Soloway M.S., Briggman J.V., Carpinito G.A., et al. Use of a new marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 156:1996;363-367.
5. Sarosdy M.F., Hudson M.A., Ellis W.J., et al. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology. 50:1997;349-353.
6. Leyh H., Marberger M., Conort P., et al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol. 35:1999;52-56.
7. Ishak L.M., Enfield D.L., Sarosdy M.F. Detection of recurrent bladder cancer using a new quantitative assay for bladder tumor. J Urol. 157A:1997;337.
8. Van der Poel H.G., Witjes J.A., van Stratum P., et al. Quanticyt karyometric analysis of bladder washings for patients with superficial bladder cancer . Urology. 48:1996;357-364.
9. Fradet Y., Lockhart C. Performance characteristics of a new monoclonal antibody test for bladder cancer Immunocyt TM . Can J Urol. 4:1997;400-405.
10. Mian C., Pycha A., Wiener H., et al. Immunocyt a new tool for detecting transitional cell cancer of the urinary tract . J Urol. 161:1999;1486-1489.
11. Sanchez-Carbayo M., Herrero E., Megias J., et al. Initial evaluation of the diagnostic performance of the new urinary bladder cancer test as a tumor marker for transitional cell carcinoma of the bladder. J Urol. 161:1999;1110-1115.
12. Mian C., Lodde M., Haitel A., et al. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology. 55:2000;223-226.
13. Moll R., Achtstätter T., Becht E., et al. Cytokeratins in normal and malignant epithelium maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines . Am J Pathol. 132:1988;123-144.
14. Sobin LH, and Wittekind C: UICC TNM Classification of Malignant Tumours, 5th ed. New York, Wiley Liss, 1997, pp 187-190.
15. Kinders R., Jones T., Root R., et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res. 4:1998;2511-2520.
16. Sanchez-Carbayo M., Herrero E., Megias J., et al. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol. 162:1999;1951-1956.
17. Myanaga N., Akaza H., Ishikawa S., et al. Clinical evaluation of nuclear matrix protein (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol. 31:1997;163-168.
18. Witjes J.A., van der Poel H.G., van Balken M.R., et al. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol. 33:1998;387-391.
19. Leyh H., Marberger M., Conort P., et al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol. 35:1999;52-56.
20. Pode D., Shapiro A., Wald M., et al. Noninvasive detection of bladder cancer with the BTA stat test. J Urol. 161:1999;443-446.
21. Sharma S., Zippe C.D., Pandrangi L., et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 162:1999;53-57.